

Claims:

1. An apheresis device comprising a solid carrier capable of being contacted with the blood or plasma flow, characterized in that the solid carrier includes an amyloid- $\beta$ -precursor-protein(APP)-binding receptor.
2. A device according to claim 1, characterized in that the APP-binding receptor is selected from anti-APP antibodies, anti-A $\beta_{40}$  antibodies, anti-A $\beta_{42}$  antibodies, APP-binding proteins, in particular gelsolin, apoJ or apoE, APP-binding peptides, APP-binding gangliosides, in particular GM1, or APP-binding nucleic acids, in particular aptamers, or mixtures of these receptors.
3. A device according to claim 1 or 2, characterized in that the carrier is a sterile and pyrogen-free column.
4. The use of a device according to any one of claims 1 to 3, for providing a treatment of Alzheimer's Disease or for prevention of the latter.